Tirzepatide for reducing the risk of major adverse cardiovascular events in people with type 2 diabetes and cardiovascular disease ID6733Status:In development | In consultationProgramme:Technology appraisal guidanceConsultation end date: 11 August 2026Expected publication date: TBC